The U.S. Food and Drug Administration declined to approve Enzyvant’s regenerative tissue therapy for a rare immunodeficiency disorder and raised concerns about the privately held drug developer’s manufacturing.
Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis, in a drive to better control production of the world’s priciest medicines.
Teva Pharmaceuticals has done an about-face and will resume production of the company’s generic chemotherapy drug vincristine, which has been described as a “lynchpin” in the treatment of many childhood cancers.
Mallinckrodt Plc received a subpoena from the U.S. Securities and Exchange Commission for documents related to the drugmaker’s lawsuit against the U.S. Department of Health and Human Services (HHS).
India’s ability to produce affordable generic drugs has led to the country’s reputation of being the “pharmacy of the world,” according to Dr. Reddy’s Vice President Radha Iyer.
U.S. President Donald Trump signed an executive order aimed at spurring the development of better vaccines to protect against seasonal influenza as well as a potential pandemic flu outbreak.
Tumble blender technology enhances the speed and homogeneous blending of tablets and capsules with trace levels of additives To meet stringent regulatory requirements, such as the United States […]
B. Braun Medical Inc. announced Solutions for Life, a $1 billion investment in new and enhanced IV therapy manufacturing facilities to help ensure a reliable and consistent supply of vital IV fluids that American health care providers need every day.
GlaxoSmithKline is investing heavily in a Montana manufacturing facility that specializes in the manufacture of the company’s two-year-old shingles vaccine Shingrix, which is eying blockbuster status.
Fresenius Kabi is investing $100 million in expanding the German company’s manufacturing campus in Wilson County, North Carolina, which will add at least 445 new jobs.
